Lucintel Forecasts the Global Daptomycin Market to Grow with a CAGR of 4.5% from 2024 to 2030

Lucintel Forecasts the Global Daptomycin Market to Grow with a CAGR of 4.5% from 2024 to 2030

Blog Article

According to a market report by Lucintel, the future of the global daptomycin market looks promising with opportunities in the 300mg and 500mg markets. The global daptomycin market is expected to grow with a CAGR of 4.5% from 2024 to 2030. The major drivers for this market are increasing population affected by skin and skin structure infections and expanding application as an antibacterial agent, and increasing bloodstream infections, such as sepsis.

A more than 150-page report to understand trends, opportunity and forecast in daptomycin market to 2030 by indication (complicated skin structure infections and bacteremia), age group (pediatric and adult), strength (300mg and 500mg), and region (North America, Europe, Asia Pacific, and the Rest of the World).

Lucintel forecasts that complicated skin structure infections will remain the larger segment over the forecast period due to heightened research and development initiatives.

Within this market, 500mg will remain the larger segment due to its efficacy and stability.

North America will remain the largest over the forecast period due to growing several government initiatives.

Teva Pharmaceuticals Industries, Merck, Cipla, copyright, BE Pharmaceuticals, Reddy’S Laboratories, Mylan, Fresenius Kabi, Nichi-Iko Pharmaceutical, Novo Holdings are the major suppliers in the daptomycin market.

This unique research report will enable you to make confident business decisions in this globally competitive marketplace. For a detailed table of contents, contact Lucintel at +1-972-636-5056 or write us at [email protected]. To get access of more than 1000 reports at fraction of cost visit Lucintel's Analytics Dashboard.

About Lucintel

At Lucintel, we offer solutions for you growth through game changer ideas and robust market & unmet needs analysis. We are based in Dallas, TX and have been a trusted advisor for 1,000+ clients for over 20 years. We are quoted in several publications like the Wall Street Journal, ZACKS, and the Financial Times.

Contact:
Roy Almaguer
Lucintel
Dallas, Texas, USA
Email: [email protected]
Tel. +1-972-636-5056